MMManabu Muto

Manabu Muto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Manabu Muto has a total of 57 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • MULTICENTER STUDY DESIGN OF THE EX VIVO EVALUATION OF ENDOCYTOSCOPY IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA

    by Manabu Muto, Mitsuhiro Fujishiro, Yoshitaka Sato, Yasumasa Niwa, Mitsuru Kaise, Mototsugu Kato, Kaiyo Takubo


  • Open Access

    Feasibility of Oxaliplatin and Infusional Fluorouracil/Leucovorin (FOLFOX4) for Japanese Patients with Unresectable Metastatic Colorectal Cancer

    by Nozomu Fuse, Toshihiko Doi, Atsushi Ohtsu, Satoshi Takeuchi, Takashi Kojima, Keisei Taku, Makoto Tahara, Manabu Muto, Masahiro Asaka, Shigeaki Yoshida

    A combination of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) is one of the standard regimens for palliative and adjuvant chemotherapy for colorectal cancer. However, the feasibility of FOLFOX4 for Japanese patients has not been determined. We conducted this prospective study to evaluate the feasibility of FOLFOX4. Previously treated or untreated patients with unresectable metastatic colorectal cancer were enrolled. The primary endpoint was the rate of completion which was defined as completion of the first 4 cycles with relative dose-intensity of oxaliplatin of 80% or higher. Of the 32 enrolled patients, 31 received FOLFOX4. Twenty-four patients (75%) had received prior chemotherapy. The rate of completion of the first four cycles was 87% (27/31; 95% CI, 70.2–96.4%). With the median number of cycles of nine (range, 1–26), grade 3 or 4 hematological toxicity and non-hematological toxicity were seen in 12 (39%) and 5 (16%) patients, respectively. Grade 1 or 2 sensory neuropathy was seen in 28 patients (90%), but no grade 3 or 4 neuropathy was seen. Grade 1 or 2 allergic reaction was seen in five patients (16%). One patient developed fatal interstitial pneumonitis and died of respiratory failure. Objective response rate was 28.6% (6/21; 95% CI, 11.3–52.2%) in the patients with measurable lesions. Median progression-free survival was 6.5 months (95% CI, 4.6–8.5 months) in all patients. The completion rate of the first four cycles was as high as expected with manageable toxicity, although fatal pneumonitis developed in one case. FOLFOX4 is feasible for Japanese patients.


  • ENDOSCOPIC DIAGNOSIS OF INTRAEPITHELIAL SQUAMOUS NEOPLASIA IN HEAD AND NECK AND ESOPHAGEAL MUCOSAL SITES

    by Manabu Muto, Yasushi Sano, Satoshi Fujii, Atsushi Ochiai, Shigeaki Yoshida


  • NARROW‐BAND IMAGING COMBINED WITH MAGNIFIED ENDOSCOPY FOR CANCER AT THE HEAD AND NECK REGION

    by Manabu Muto, Toru Ugumori, Yasush I Sano, Atsushi Ohtsu, Shigeaki Yoshida

    While detection of lesions at an earlier stage in head and neck mucosal sites would obviously be of great merit to patients, there has been no modality to discover such lesions. Herein, we investigate a possibility of clinical application of narrow‐band imaging (NBI) endoscopy, which is a brand new optical technique that allows non‐invasive visualization of the microvessels at the organ surface. We found that NBI technology could be a promising and powerful tool for identifying carcinomas at an earlier stage in head and neck mucosal sites. This may open a new door in the field of head and neck oncology.


  • Open Access

    Risk of multiple squamous cell carcinomas both in the esophagus and the head and neck region

    by Manabu Muto, Mari Takahashi, Atsushi Ohtsu, Satoshi Ebihara, Shigeaki Yoshida, Hiroyasu Esumi

    While multiple squamous cell carcinomas are often observed in the esophagus and the head and neck region and confound us about the favorable treatments, the reason why some patients are more likely to develop multiple cancers remains obscure. We statistically analyzed clinical factors in 203 patients with newly diagnosed squamous cell carcinoma, to assess the risk of multiple cancers for the establishment of an effective prevention and screening programs. Widespread epithelial oncogenic alterations were assessed as multiple lugol-voiding lesions (multiple LVL) using lugol chromoendoscopy. Genetic polymorphisms of alcohol dehydrogenase type 3 (ADH3) and aldehyde dehydrogenase type 2 (ALDH2) were identified by PCR–restriction fragment length polymorphism analysis. Forty patients had synchronous multiple cancers and the remaining 163 had solitary cancer. Presence of multiple LVL was the only independent risk factor for multiple cancers [relative risk (RR) = 67; 95%CI, 15–310]. Multiple LVL was observed in only smoking drinkers. Among them, a multivariate analysis demonstrated that the ALDH2 deficiency allele (RR = 5.7; 95%CI, 2.8–11.6) and the slow metabolizing ADH3 allele (RR = 1.9; 95%CI, 1.1–7.9) were the independent risk factors for multiple LVL. Combination of these alleles lead to increase the risk of multiple LVL. In conclusion, an episode of multiple LVL is a remarkable high risk for multiple cancers both at the esophagus and the head and neck region. The interaction between drinking and the ALDH2 deficiency allele increases the risk. In addition, the slow metabolizing ADH3 allele enhances the risk. Prohibiting the use of alcohol and early detection of cancer are strongly recommended for such individuals.


  • Endoscopic Mucosal Resection in the Stomach Using the Insulated-Tip Needle-Knife

    by M. Muto, S. Miyamoto, A. Hosokawa, T. Doi, A. Ohtsu, S. Yoshida, Y. Endo, K. Hosokawa, D. Saito, C.-S. Shim, et al.

    Endoscopic mucosal resection (EMR) is now accepted as a standard treatment for intramucosal gastric cancer in Japan. Since Tada et al. described the strip biopsy method in 1983 [ 1 ], this technique has been widely used not only in Japan but also in other countries and has been improved in a variety of ways [ 2 ]. According to the guidelines for the treatment of gastric cancer from by the Japanese Gastric Cancer Association, the indications for EMR are: intramucosal cancer; a diameter of 20 mm or less; intestinal type, histologically; and no findings of ulcer. However, with conventional techniques such as the strip biopsy method, it is difficult to obtain a large specimen as a ”one-piece” or ”en bloc” resection. The most important issue in curing cancer is achieving a complete resection. ”Multi-fragment” or piecemeal resection makes it difficult to histologically evaluate the completeness of the resection, which can occasionally result in incomplete treatment leading to local tumor recurrence. Therefore, en bloc resection with an adequate margin that has no tumor cells (i. e. that is tumor cell-negative) is ideal for successful treatment. In 1988 Hirao et al. developed another EMR technique for en bloc resection, using the electrosurgical needle-knife, that is, endoscopic resection with local injection of hypertonic saline-epinephrine solution for hemostasis [ 3 ]. This technique increased the rate of curative resection remarkably; however, the cutting power required for mucosal incision (150 W) is so great that perforation is likely to occur if there is not a high degree of skill on the part of the clinician. In order to overcome the above disadvantage, Hosokawa developed a new needle-knife, i. e. the insulated-tip diathermic electrosurgical knife, which has a ceramic ball at the top of the incising needle to prevent electrical leakage toward the deeper layer of the stomach [ 4 ]. Experimentation with a pig’s stomach showed that the insulated-tip knife resected only the mucosa and submucosa without histologically evident burning effects in the serosa, and it was successfully used to resect dog gastric mucosa in vivo. After these promising experimental results in animal models, in 1994 Hosokawa introduced the use of the device in the clinic at the National Cancer Centre Hospital East (NCCHE), Chiba, Japan [ 4 ]. Ohkuwa et al. were the first to report the efficacy and complications of EMR using the insulated-tip knife for intramucosal gastric neoplasms [ 5 ]. Miyamoto et al. reported on the feasibility of EMR with the insulated-tip knife as a standard technique in clinical practice [ 6 ].


  • Top Cited Papers

    Squamous cell carcinoma in situ at oropharyngeal and hypopharyngeal mucosal sites

    by Manabu Muto, Mari Nakane, Chikatoshi Katada, Yasushi Sano, Atsushi Ohtsu, Hiroyasu Esumi, Satoshi Ebihara, Shigeaki Yoshida

    BACKGROUND: Head and neck squamous cell carcinoma typically is diagnosed at an advanced stage, and the prognosis for patients with this type of malignancy is poor. Detection of these lesions at an earlier stage (e.g., as carcinoma in situ) would be of clear benefit to patients. However, it has been extremely difficult to detect carcinoma in situ at head and neck mucosal sites during routine endoscopy, even after numerous passes of the endoscope through the oral cavity and the pharynx.METHODS: The current clinical investigation was performed during routine endoscopic screening or surveillance procedures. The authors used a novel optical technique, known as narrowband imaging (NBI) that allows noninvasive visualization of the microvascular structure of an organ's surface using reflected light.RESULTS: Between April 2002 and August 2003, 34 consecutive superficial lesions were found in 18 patients. Multifocal carcinoma was found in 5 patients (28%). The median age of the patients examined was 59.5 years (range, 43–71 years), and 83% of all patients were male. All lesions exhibited a microvascular proliferation pattern on magnified NBI. Thirteen patients with a combined total of 29 lesions underwent endoscopic resection under general anesthesia. The pyriform sinus was the most frequent primary site (66%; 19 of 29 lesions). The median tumor diameter was 20 mm (range, 1.3–40 mm). Twenty‐one lesions (72%) were histologically confirmed to be carcinoma in situ, and the remaining lesions showed evidence of microinvasion (0.05–1 mm) beneath the epithelium. Vascular invasion was observed in only one lesion. The median hospital stay was 10 days (range, 4–18 days). All patients were discharged without severe complications. After a median follow‐up period of 8 months (range, 1–16 months), there were no cases of local disease recurrence.CONCLUSION: The authors stress the importance of endoscopic detection of superficial carcinoma at oropharyngeal and hypopharyngeal mucosal sites. NBI is a promising and potentially powerful tool for identifying carcinomas at an earlier stage during routine endoscopic examination. Cancer 2004. © 2004 American Cancer Society.


    • 1 September 2003
      • Vol. 30  (9) , 1230-7

    [Controversies in the treatment of esophageal cancer from the viewpoint of medical oncology].

    by Atsushi Ohtsu, Manabu Muto, Kiyomi Mera, Satoshi Ishikura

    Recent advances in non-surgical treatments such as endoscopic mucosal resection (EMR) and chemoradiotherapy (CRT) have provided various advantages with clinically meaningful impacts in the treatment of esophageal cancer. EMR is a standard treatment for mucosal cancer and is being investigated for use in combination with CRT for submucosal cancer. Definitive CRT has also reported to results in survival mostly comparable with surgery in the loco-regional stage. A randomized trial comparing surgery alone with definitive CRT in stage I disease is also planned. In patients with T4 disease, it appears that CRT is becoming a standard. However, various issues and limitations remain with non-surgical treatments. To improve treatment results, closer collaboration between surgeons and radiation oncologists is necessary.